Abstract:Given the essential role of Epigenetic regulation in many biological processes, targeted epigenetic drugs have been gradually applied to the treatment of tumors. Histone deacetylases (HDACs) are a class of epigenetic enzymes, which play key roles in chromosome structural modification and gene expression regulation. Targeted microtubules drugs have achieved great success in clinical application for decades. Development of novel agents with multitargeting capabilities specially dual-target has become a popular research field for the treatment of human cancers, which may provide synergistic anticancer effects. Here, we reported a novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo. Compound SY-65 was identified as a dual inhibitor of tubulin/HDAC1 (IC50 = 3.64 and 0.529 μM, respectively) with excellent antiproliferative activity against MGC-803, HCT-116, KYSE-450, HGC-27, SGC-7901 and MKN-45 cells. Especially, compound SY-65 exhibited potent antiproliferative activity against MGC-803, HGC-27 and SGC-7901 cells with IC50 values <55 nM, which was better than that of Colchicine, MS-275 and SAHA. Compound SY-65 effectively inhibited tubulin polymerization and bound to the colchicine binding site of tubulin, as well as inhibited HDAC1 activity both intra/extracellularly. Molecular docking results suggested there were the well-defined binding modes of compound SY-65 in HDAC1 and tubulin. In addition, compound SY-65 inhibited colony formation, interfered with the cell cycle distribution, induced cell cycle arrest at the G2/M phase and apoptosis in MGC-803 and HGC-27 cells. Compound SY-65 also exhibited a good tumor inhibitory effect in vivo without obvious toxicity. Therefore, compound SY-65 could be developed as a novel tubulin/HDAC1 candidate inhibitor for future cancer therapeutics.

Discovery of Chiral 1,4-Diarylazetidin-2-one-Based Hydroxamic Acid Derivatives as Novel Tubulin Polymerization Inhibitors with Histone Deacetylase Inhibitory Activity

Discovery of Novel Tubulin/hdac Dual-Targeting Inhibitors with Strong Antitumor and Antiangiogenic Potency.

Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma

Discovery of a Chiral Fluorinated Azetidin-2-one As a Tubulin Polymerisation Inhibitor with Potent Antitumour Efficacy

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.

Design, synthesis and antitumor evaluation of novel chiral diaryl substituted azetidin-2-one derivatives as tubulin polymerization inhibitors

Discovery of Novel Arylamide Derivatives Containing Piperazine Moiety As Inhibitors of Tubulin Polymerisation with Potent Liver Cancer Inhibitory Activity.

Design, Synthesis and Evaluation of Dihydro-1H-indene Derivatives As Novel Tubulin Polymerisation Inhibitors with Anti-Angiogenic and Antitumor Potency.

Design, synthesis, and biological evaluation of diaryl heterocyclic derivatives targeting tubulin polymerization with potent anticancer activities

Design, Synthesis and Biological Evaluation of Novel Diarylpyridine Derivatives As Tubulin Polymerisation Inhibitors

Design, Synthesis and Biological Evaluation of Novel Dihydroquinolin-4(1H)-one Derivatives As Novel Tubulin Polymerization Inhibitors

Discovery of Novel 4-Arylisochromenes As Anticancer Agents Inhibiting Tubulin Polymerization.

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

Synthesis, biological evaluation and molecular docking of thiazole hydrazone derivatives grafted with indole as novel tubulin polymerization inhibitors

A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo

Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors

Design, Synthesis and Biological Evaluation of Colchicine Derivatives As Novel Tubulin and Histone Deacetylase Dual Inhibitors

2-Methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response.

Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors

Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis